IGF-1 LR3

Step	Weeks	Dose	Purpose
Week 1	—	20 mcg	Assess hypoglycemia risk
Weeks 2-6	—	40-80 mcg	Muscle hypertrophy protocol

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Reconstitution and handling notes

Stacking Notes

Additional Dosage Notes

Foundational Pharmacology - Francis, Tomas

The fundamental pharmacologic characterization of IGF-1 LR3 came from researchers at CSIRO Australia in the early 1990s, primarily for cell culture bioreactor applications rather than clinical therapy:

• [Francis et al., 1992] described the IGFBP-binding properties of LR3 and demonstrated the dramatic increase in free/bioactive IGF-1 fraction
• [Tomas et al., 1992; PMID:1371669] documented anabolic effects in dexamethasone-treated rodent models - improved nitrogen balance and muscle protein synthesis - and found the IGFBP-poorly-binding variants (including LR3-IGF-I) to be ~2.5x more potent than native IGF-I despite LR3 binding the type-1 IGF receptor ~3-fold more weakly

This foundational work established IGF-1 LR3 as a research tool but never progressed toward clinical drug development.

Mecasermin Parallel (FDA-Approved Native IGF-1)

Recombinant native human IGF-1 (mecasermin, brand Increlex) received FDA approval in 2005 for severe primary IGF-1 deficiency (SPIGFD) in children - a rare genetic syndrome where the pituitary produces GH but downstream IGF-1 production fails. The mecasermin clinical program provides the closest analog of IGF-1 receptor pharmacology in humans:

• Twice-daily SC injection (short half-life of native IGF-1 requires frequent dosing)
• Typical pediatric dose: 40-120 mcg/kg BID
• Primary adverse event: hypoglycemia, more pronounced in first month
• Long-term observation: accelerated linear growth; lymphoid/thymic hypertrophy; tonsillar hypertrophy; occasional otitis media

The mecasermin experience informs IGF-1 LR3 safety expectations: the hypoglycemia risk is real, and the tissue-wide growth effects (tonsillar hypertrophy, lymphoid tissue enlargement) confirm the ubiquitous receptor distribution.

Muscle IGF-1 Research - Adams, Barton-Davis

The basic biology of IGF-1 in muscle has been extensively studied:

• [Adams & Haddad, 1998] documented IGF-1's central role in skeletal muscle hypertrophy in response to loading
• [Barton-Davis et al., 1998] demonstrated in aging mice that local muscle IGF-1 overexpression preserved muscle mass and prevented sarcopenia-related strength loss
• Muscle-specific IGF-1 splice variants (mechano-growth factor, MGF) were identified as key mediators of exercise-induced muscle adaptation

This literature supports the mechanistic rationale for IGF-1 anabolic protocols but doesn't directly validate IGF-1 LR3 in humans at the doses used for performance purposes.

No Direct Adult Human Anabolic Trials

Unlike GLP-1 agonists (dozens of phase 3 trials) or even the GHRP compounds (diagnostic-indication approvals in Japan/Europe), IGF-1 LR3 has no published human efficacy trial data for performance or body composition indications. The off-label use in bodybuilding is based on:

• Mechanistic plausibility from native IGF-1 biology
• Cell culture and animal model anabolic effects
• Observational reports from the peptide therapy and bodybuilding communities (not peer-reviewed)
• Inference from mecasermin pediatric safety/efficacy data

This is a genuine evidence gap. Users should understand that the dosing and efficacy claims circulating in the bodybuilding community are extrapolations, not validated clinical recommendations.

IGF-1 Biology Reviews - Clemmons, Frystyk

[Clemmons, 2009] and [Frystyk, 2010] provide comprehensive reviews of IGF-1 system biology in adults, establishing the physiologic framework within which IGF-1 LR3's effects operate:

• IGF-1 is a potent anabolic and anti-catabolic signal in skeletal muscle
• Sustained supraphysiologic IGF-1 has mechanistic cancer-promotion concerns (IGF-1 is a growth factor; virtually all malignancies overexpress IGF1R)
• IGFBPs are essential for normal IGF-1 physiology - the LR3 modifications bypass this safety system
• Tissue-specific responses to IGF-1 depend on local IGFBP expression patterns

Safety Signal Summary

The safety profile of IGF-1 LR3 in humans is inferred from:

• Mecasermin trials: Hypoglycemia, lymphoid hypertrophy, occasional otitis media - no major serious AE signal with short-term dosing
• Observational bodybuilding use: Hypoglycemia (common), peripheral tissue growth with chronic high-dose use (gut hypertrophy, potential cardiac hypertrophy), no documented large-population malignancy signal but no large-population studies either
• Mechanistic concerns: Sustained supraphysiologic mitogenic signaling in a receptor expressed ubiquitously, including on malignant cells

The absence of long-term human safety data specifically for IGF-1 LR3 at performance-dosing levels is a critical knowledge gap. Users should weigh the potent short-term anabolic effects against unknown long-term risks.

Acute and Common

• Hypoglycemia — The primary acute safety concern. Post-injection blood glucose drops can produce shakiness, sweating, confusion, palpitations, and in severe cases loss of consciousness. Mitigation: 30-40g of fast-digesting carbohydrate within 30 minutes of injection; avoid combining with insulin or aggressive carb restriction; test blood glucose during first weeks of dosing.
• Injection site reactions — Mild erythema and transient itching at SC site. Site rotation minimizes.
• Mild hunger — From insulin-receptor activation and blood glucose effects, not ghrelin pathway. Less pronounced than with GHRP compounds.
• Slight warmth or flushing — Occasional, short-lived.

Less Common (Early)

• Jaw/temporomandibular pain — Reported by some users particularly in first weeks; possibly related to growth effects on facial muscles or connective tissue
• Mild facial puffiness — Water retention and soft-tissue growth
• Localized muscle soreness at injection site — Occasionally severe in users who inject intramuscularly (IM) rather than SC
• Transient fatigue — Usually in association with early hypoglycemic episodes
• Headache — Mild, usually responsive to hydration

Dose-Dependent with Chronic Use

• Peripheral tissue growth / "IGF gut" — Intestinal epithelial hypertrophy produces a distinctive abdominal distension at high cumulative doses. This is an IGF-1 receptor expression phenomenon — the gut lining is highly proliferative and IGF1R-positive, so chronic high-dose IGF-1 LR3 drives measurable gut tissue growth. Reversible with discontinuation but takes weeks to months to fully resolve.
• Organ enlargement — Liver, spleen, kidneys all express IGF1R. Chronic high-dose use can produce organomegaly detectable on imaging. Most users never develop this at typical bodybuilding doses, but the risk scales with dose and duration.
• Cardiac hypertrophy — Theoretical concern. The heart responds to IGF-1 signaling; prolonged supraphysiologic exposure could contribute to left ventricular hypertrophy. Generally not clinically significant at typical use patterns but warrants periodic echocardiographic monitoring in long-term users.
• Lymphoid tissue hypertrophy — Tonsillar enlargement, adenoid hypertrophy, occasionally submandibular lymph node enlargement. Documented in mecasermin pediatric trials; likely applies to IGF-1 LR3 at sufficient dose/duration.

Long-term Theoretical

• Cancer risk — This is the most important theoretical concern. IGF-1 is a pro-mitogenic signal; virtually every malignancy overexpresses IGF1R; elevated IGF-1 is a risk factor for breast, prostate, and colon cancers in epidemiologic studies. Sustained supraphysiologic IGF-1 LR3 signaling has mechanistic plausibility for cancer promotion in users with any pre-existing occult malignancy or strong predisposition. No large-population longitudinal data exists to quantify this risk in performance-dose LR3 users specifically, but the mechanism is well-established and conservative dosing with periodic screening is warranted.
• Acromegalic changes — Soft tissue growth effects (enlarged hands/feet, facial bone remodeling) with very chronic high-dose use approaching acromegaly-like patterns. More common in exogenous HGH abuse but possible with sustained IGF-1 LR3.
• Diabetes risk — Chronic insulin-receptor cross-activation could theoretically contribute to beta-cell exhaustion or insulin resistance patterns over very long timescales.

Serious but Rare

• Severe hypoglycemia with loss of consciousness — Usually preventable with appropriate carbohydrate management
• Symptomatic organomegaly — Abdominal fullness, early satiety, or imaging abnormalities
• Unexpected new growth of pre-existing moles or tumors — Immediate discontinuation and oncology evaluation

Signs You Need to Stop

• Any unexplained new or changing mass, lymphadenopathy, or pigmented lesion
• Symptomatic abdominal distension or early satiety (suggesting gut/organ growth)
• Persistent fasting glucose or HbA1c elevation
• New chest pain, shortness of breath, or cardiovascular symptoms
• Any signs of organomegaly on physical exam or imaging
• Disproportionate lymphoid tissue enlargement (large tonsils, adenoids, or nodes)